Antiprotease therapy in cancer: hot or not? (Q36407244)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Antiprotease therapy in cancer: hot or not? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

María Beatriz Durán Alonso

17 January 2020

author

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Tamara T Lah

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Cornelis J F Van Noorden

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

257-279

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

Genetic predisposition to colorectal cancer

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

BRCA1 and BRCA2: 1994 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Genomic instability--the engine of tumorigenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

BRAFE600-associated senescence-like cell cycle arrest of human naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Epithelial-mesenchymal transitions in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Tumour-cell invasion and migration: diversity and escape mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Metastasis suppressors alter the signal transduction of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Dissecting the metastatic cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

The fallacy of epithelial mesenchymal transition in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Human and mouse proteases: a comparative genomic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Chemical approaches to the discovery and development of cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Matrix metalloproteinases as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

An overview of current delivery systems in cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Cell-surface cathepsin B: Understanding its functional significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Proteases in brain tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Matrix metalloproteinases in tumor-host cell communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Kupffer cells and pit cells are not effective in the defense against experimentally induced colon carcinoma metastasis in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

New functions for the matrix metalloproteinases in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Secreted cathepsin L generates endostatin from collagen XVIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Friends or foes - bipolar effects of the tumour stroma in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Coevolution of cancer and stromal cellular responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Metronomic scheduling: the future of chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Paracrine factor and cell-cell contact-mediated induction of protease and c-ets gene expression in malignant keratinocyte/dermal fibroblast cocultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Functional imaging of proteolysis: stromal and inflammatory cells increase tumor proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Tumour-educated macrophages promote tumour progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Membrane associated proteases and their inhibitors in tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Action of rat liver cathepsin L on collagen and other substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Imaging of cancer invasion and metastasis using green fluorescent protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Metalloproteinases and their inhibitors in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

RECKing MMP function: implications for cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

The ADAM gene family: surface proteins with adhesion and protease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

The ADAMTS metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Development of molecular targeted anticancer agents: successes, failures and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Matrix metalloproteinase inhibitors as anticancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Increased surgical stress promotes tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

The effect of low molecular weight heparin on survival in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Emerging roles for cysteine proteases in human biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Destination 'lysosome': a target organelle for tumour cell killing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Lysosomes and autophagy in cell death control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Photochemical internalisation: a novel drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Cysteine cathepsins in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Expression of cathepsin D during the progression of human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

In vivo inhibition of cysteine proteinases delays the onset of growth of human pancreatic cancer explants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Cathepsin L in glioma progression: comparison with cathepsin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Senescence-initiated reversal of drug resistance: specific role of cathepsin L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Deficiency of the cysteine protease cathepsin S impairs microvessel growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Cathepsin L is required for endothelial progenitor cell-induced neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Proteasome inhibition as a therapeutic strategy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

A giant protease with potential to substitute for some functions of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Mitotic infidelity and centrosome duplication errors in cells overexpressing tripeptidyl-peptidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

An update on human and mouse glandular kallikreins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Calpain: a role in cell transformation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

v-Src-induced modulation of the calpain-calpastatin proteolytic system regulates transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Calpain activity is generally elevated during transformation but has oncogene-specific biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Versatile prostate cancer treatment with inducible caspase and interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Cancer nanotechnology: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Local endostatin treatment of gliomas administered by microencapsulated producer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Strategies for MMP inhibition in cancer: innovations for the post-trial era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Visualization of early events in tumor formation of eGFP-transfected rat colon cancer cells in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

Age dependence of ischaemic heart syndromes and the contribution of haemostatic deviations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

A proteolytic system that compensates for loss of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.257

21 January 2018

Identifiers

DOI

10.1517/14712598.6.3.257

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16503735%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference